Drug intelligence / Profile preview

Enterococcus faecium LMG S-28935 + Saccharomyces boulardii MUCL 53837

Development stage
Preclinical
Lead developer
ENBIOSIS Biotechnology
Modality
Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration
Oral
01

Overview

This product is a combination of two probiotic strains, Enterococcus faecium LMG S-28935 and Saccharomyces boulardii MUCL 53837. Both are live microorganisms used as probiotics to promote gut health and restore or maintain the balance of intestinal microbiota. **Enterococcus faecium** is a lactic acid bacterium known for its ability to survive the digestive process, adhere to intestinal surfaces, compete with pathogenic bacteria for resources and adhesion sites, stimulate immune function, regulate cell proliferation in the gut epithelium, and potentially lower cholesterol levels[2][3][4]. It has been studied for use in preventing or treating antibiotic-associated diarrhea, irritable bowel syndrome (IBS), and other gastrointestinal disorders[4]. **Saccharomyces boulardii** is a non-pathogenic yeast widely used as a probiotic for prevention and treatment of various forms of diarrhea (including antibiotic-associated diarrhea), Clostridioides difficile infection recurrence prevention, traveler’s diarrhea prophylaxis/treatment, and support during Helicobacter pylori eradication therapy. Its mechanisms include restoration of normal gut flora balance after disruption by antibiotics or illness; secretion of factors that inhibit pathogen adherence; modulation of local immune responses; degradation of bacterial toxins; enhancement of mucosal barrier function; and anti-inflammatory effects. The combination aims to provide synergistic benefits by combining bacterial (E. faecium) with yeast (S. boulardii) probiotics—potentially broadening antimicrobial activity against pathogens while supporting both immune modulation and restoration/maintenance of healthy gut flora.

Other names
Enterococcus faecium LMG S-28935Saccharomyces boulardii MUCL 53837
02

Targets

Shigella spp. (Shigella species)

Beyond the preview

Go deeper on Enterococcus faecium LMG S-28935 + Saccharomyces boulardii MUCL 53837.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enterococcus faecium LMG S-28935 + Saccharomyces boulardii MUCL 53837.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call